ACORDA THERAPEUTICS INC's gross profit margin for the third quarter of its fiscal year 2023 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. ACORDA THERAPEUTICS INC has weak liquidity. Currently, the Quick Ratio is 0.98 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has decreased by 22.18% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 27.72 | 33.51 |
EBITDA ($mil) | 0.2 | -1.77 |
EBIT ($mil) | -7.72 | -9.56 |
Net Income ($mil) | -8.89 | -13.85 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 33.33 | 33.93 |
Total Assets ($mil) | 366.34 | 393.34 |
Total Debt ($mil) | 186.09 | 193.76 |
Equity ($mil) | 58.96 | 75.77 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | 88.6 | 67.47 |
EBITDA Margin | 0.7 | -5.28 |
Operating Margin | -27.86 | -28.54 |
Sales Turnover | 0.3 | 0.32 |
Return on Assets | -4.35 | -26.85 |
Return on Equity | -27.06 | -139.41 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 1.59 | 1.71 |
Debt/Capital | 0.76 | 0.72 |
Interest Expense | 7.98 | 7.47 |
Interest Coverage | -0.97 | -1.28 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 1.24 | 1.22 |
Div / share | 0.0 | 0.0 |
EPS | -7.16 | -11.4 |
Book value / share | 47.47 | 62.27 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 4036.0 | 6179.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 0.27 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 19.07. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, ACORDA THERAPEUTICS INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ACOR NM | Peers 85.83 | ACOR NM | Peers 38.76 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. ACOR's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. ACOR's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
ACOR NA | Peers 18.08 | ACOR NA | Peers 1.16 | |||||||||||||||||||||
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential. Ratio not available. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
ACOR 0.27 | Peers 19.07 | ACOR 87.66 | Peers 12.58 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. ACOR is trading at a significant discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. ACOR is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
ACOR 0.14 | Peers 84.44 | ACOR -10.44 | Peers 42.35 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. ACOR is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. ACOR significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||